Humanized Immune System Mice

Ready-to-use: single batch delivery capacity of over 500 mice. Stable & Reliable: Pre-tested, meets industry reconstitution benchmark (hCD45+ ≥ 25%). Extended Survival: Over 90% survival rate at 250 days (35+ weeks) post huHSC reconstitution, ideal for long-term studies including toxicology and safety assessment. Proprietary model with high-impact literature support (total IF > 5000), data available on official website.

The core advantage of huPBMC-NCG lies in its rapid, T cell-focused reconstitution, enabling high-efficiency acquisition of human T cell experimental data within 7–14 days. It is suitable for short-term CDX/PDX models and the construction of autoimmune disease models using patient-derived PBMC/PBL. In contrast, huHSC-NCG is characterized by its comprehensive and long-lasting reconstitution, achieving multi-lineage and multi-organ hematopoietic reconstitution over 8–12 weeks. It is applicable to long-term CDX/PDX models, autoimmune and infection models (reconstitution combined with inducers), and features extended survival cycles with high stability, making it particularly suitable for long-term pharmacodynamic evaluation.